Albumin-binding nanocomplexes for delivery of combination siRNA therapeutics to KRAS-driven cholangiocarcinoma
白蛋白结合纳米复合物用于向 KRAS 驱动的胆管癌递送组合 siRNA 疗法
基本信息
- 批准号:10389971
- 负责人:
- 金额:$ 7.62万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-07-01 至 2024-06-30
- 项目状态:已结题
- 来源:
- 关键词:AddressAdverse effectsAlbuminsApoptoticBindingBiologicalBiological AvailabilityBiological Response Modifier TherapyBlood CirculationBlood TestsCell DeathCell LineChemicalsChemistryChloroquineCholangiocarcinomaClinicalDiagnosisDiseaseDrug KineticsEndosomesExtrahepaticFDA approvedFRAP1 geneFaceFatty AcidsGene CombinationsGene SilencingGene TargetingGenerationsGenesGoalsHepaticHistologyImpairmentIn VitroInduction of ApoptosisInhibition of Cell ProliferationIntrahepatic CholangiocarcinomaIntravenousK-ras mouse modelKRAS oncogenesisKRAS2 geneKidneyMAP Kinase GeneMCL1 geneMalignant NeoplasmsMediatingModelingMolecularMolecular TargetMonitorMutateMutationOncogenesOncogenicOrganOutcomePathway interactionsPatientsPenetrationPharmaceutical PreparationsPrognosisPropertyQuantitative Reverse Transcriptase PCRRNA deliveryRNA-targeting therapyReporter GenesResearchResistanceResistance developmentSignal TransductionSiteSmall Interfering RNAStructureTailTechnologyTestingTherapeuticTherapeutic EffectTherapeutic Use StudyTimeTumor TissueTwin Multiple BirthUnresectableWestern BlottingWorkbasechemotherapydensitydesignexperimental studyimmunogenicityimprovedin vivointrahepaticknock-downmTOR Signaling Pathwaymolecular targeted therapiesmonolayermouse modelmutantnanocomplexesnew therapeutic targetnext generationnucleasepre-clinicalpreemptresponsesmall moleculesmall molecule therapeuticsstandard of caresubcutaneoustargeted treatmenttherapeutic RNAtherapy outcometherapy resistanttissue culturetumoruptake
项目摘要
Research Summary
Patients diagnosed with advanced cholangiocarcinoma (CCA) have poor overall outcomes and face
limited treatment options. Small interfering RNA (siRNA) therapeutics offer an attractive strategy for silencing
oncogenic drivers of CCA that lack FDA-approved molecularly-targeted therapeutics, particularly KRAS, which
is mutated in ~22% of intrahepatic and ~42% of extrahepatic CCAs. Combination siRNA therapeutics may be
devised to preempt compensatory resistance pathways that frequently arise in the course of targeted therapy.
Furthermore, siRNA may be targeted to sites of malignancy, avoiding adverse effects due to molecularly on-
target activity in healthy organs, as is seen with many small molecule drugs. However, delivery challenges
including nuclease degradation, rapid clearance, and lack of a mechanism for cellular uptake or endosome
escape have traditionally limited clinical use of siRNA. Our group has recently developed technology to
chemically modify siRNAs with twin fatty acids (siRNA-L2) that form non-covalent nanocomplexes with
endogenous albumin (alb-NCs). Since albumin is ordinarily long-circulating in the vasculature but is actively
taken up by tumors, we have found that alb-NCs extend siRNA circulation time, promote homogeneous tumor
penetration, and increase tumor-selective siRNA uptake. Such a technology is well-suited for fibrotic tumors like
CCA, for which an active uptake mechanism is necessary for delivery of large biologic therapeutics. However,
the siRNA-L2 design has not yet been integrated with “on-board” functionality to escape from endosomes, which
represent a critical barrier to siRNA activity. In this project, I propose to optimize and tailor the siRNA-L2 alb-NC
platform to enable efficient tumor-selective knockdown of oncogenic drivers in CCA.
The studies proposed here will test the hypothesis that alb-NC-mediated delivery of a combination of
siRNAs targeting both KRAS and complementary resistance pathways will provide therapeutic benefit in KRAS-
driven cholangiocarcinoma. First, I will chemically optimize alb-NCs for efficient endosomal escape and
intracellular siRNA delivery. Second, I will credential gene targeting of KRAS in combination with rationally-
selected complementary gene targets involved in mTOR signaling or apoptotic pathways implicated in KRAS
treatment resistance. I will then perform pre-clinical therapeutic studies using alb-NCs to deliver KRAS-based
siRNA combinations to orthotopic mouse models of KRAS-mutant intrahepatic CCA. This project will thus
address a pressing need for new targeted therapeutic approaches in CCA by developing efficacious siRNA
delivery technologies to target key gene combinations in KRAS-driven disease.
研究总结
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Justin Han-Je Lo其他文献
Justin Han-Je Lo的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
相似海外基金
Unraveling Adverse Effects of Checkpoint Inhibitors Using iPSC-derived Cardiac Organoids
使用 iPSC 衍生的心脏类器官揭示检查点抑制剂的副作用
- 批准号:
10591918 - 财政年份:2023
- 资助金额:
$ 7.62万 - 项目类别:
Optimization of mRNA-LNP vaccine for attenuating adverse effects and analysis of mechanism behind adverse effects
mRNA-LNP疫苗减轻不良反应的优化及不良反应机制分析
- 批准号:
23K15383 - 财政年份:2023
- 资助金额:
$ 7.62万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Elucidation of adverse effects of combined exposure to low-dose chemicals in the living environment on allergic diseases and attempts to reduce allergy
阐明生活环境中低剂量化学品联合暴露对过敏性疾病的不良影响并尝试减少过敏
- 批准号:
23H03556 - 财政年份:2023
- 资助金额:
$ 7.62万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Green tea-based nano-enhancer as an adjuvant for amplified efficacy and reduced adverse effects in anti-angiogenic drug treatments
基于绿茶的纳米增强剂作为抗血管生成药物治疗中增强疗效并减少不良反应的佐剂
- 批准号:
23K17212 - 财政年份:2023
- 资助金额:
$ 7.62万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Effects of Tobacco Heating System on the male reproductive function and towards to the reduce of the adverse effects.
烟草加热系统对男性生殖功能的影响以及减少不利影响。
- 批准号:
22H03519 - 财政年份:2022
- 资助金额:
$ 7.62万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Mitigating the Adverse Effects of Ultrafines in Pressure Filtration of Oil Sands Tailings
减轻油砂尾矿压力过滤中超细粉的不利影响
- 批准号:
563657-2021 - 财政年份:2022
- 资助金额:
$ 7.62万 - 项目类别:
Alliance Grants
1/4-Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
1/4-破译ECT结果和不良反应的机制(DECODE)
- 批准号:
10521849 - 财政年份:2022
- 资助金额:
$ 7.62万 - 项目类别:
4/4-Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
4/4-破译ECT结果和不良反应的机制(DECODE)
- 批准号:
10671022 - 财政年份:2022
- 资助金额:
$ 7.62万 - 项目类别:
2/4 Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
2/4 ECT 结果和不良反应的破译机制(DECODE)
- 批准号:
10670918 - 财政年份:2022
- 资助金额:
$ 7.62万 - 项目类别:
Adverse Effects of Using Laser Diagnostics in High-Speed Compressible Flows
在高速可压缩流中使用激光诊断的不利影响
- 批准号:
RGPIN-2018-04753 - 财政年份:2022
- 资助金额:
$ 7.62万 - 项目类别:
Discovery Grants Program - Individual














{{item.name}}会员




